Pfizer Inc. (NYSE:PFE) Holdings Increased by Bell Bank

Bell Bank raised its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 10.5% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 366,542 shares of the biopharmaceutical company's stock after purchasing an additional 34,740 shares during the period. Bell Bank's holdings in Pfizer were worth $9,288,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Tallon Kerry Patrick acquired a new stake in Pfizer during the 4th quarter valued at $509,000. Brighton Jones LLC grew its holdings in Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after purchasing an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC grew its holdings in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after purchasing an additional 2,087 shares in the last quarter. Principal Securities Inc. grew its holdings in Pfizer by 1.9% during the 4th quarter. Principal Securities Inc. now owns 84,689 shares of the biopharmaceutical company's stock valued at $2,247,000 after purchasing an additional 1,609 shares in the last quarter. Finally, Allworth Financial LP grew its holdings in Pfizer by 12.9% during the 4th quarter. Allworth Financial LP now owns 132,932 shares of the biopharmaceutical company's stock valued at $3,458,000 after purchasing an additional 15,177 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. UBS Group raised their price objective on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target for the company. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Finally, Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. One analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Stock Performance

NYSE:PFE traded down $0.13 during mid-day trading on Thursday, hitting $23.88. The stock had a trading volume of 37,055,113 shares, compared to its average volume of 41,246,625. The stock has a market capitalization of $135.74 billion, a price-to-earnings ratio of 17.30, a P/E/G ratio of 0.87 and a beta of 0.57. The company has a 50 day simple moving average of $23.22 and a 200-day simple moving average of $24.91. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same period last year, the firm posted $0.82 EPS. Pfizer's quarterly revenue was down 7.8% compared to the same quarter last year. On average, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, June 13th. Shareholders of record on Friday, May 9th were given a dividend of $0.43 per share. The ex-dividend date was Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.20%. Pfizer's dividend payout ratio (DPR) is 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.